Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice
- 86 Downloads
Evidence suggests that GABA and CCK have opposite roles in the regulation of anxiety.
The aim of the present work was to study diazepam-induced anxiolytic-like action and impairment of motor co-ordination, and the parameters of benzodiazepine receptors in mice lacking CCK2 receptors.
The action of diazepam (0.5–3 mg/kg IP) was studied in the elevated plus-maze model of anxiety and rotarod test using mice lacking CCK2 receptors. The parameters of benzodiazepine receptors were analysed using [3H]-flunitrazepam binding.
In the plus-maze test, the exploratory activity of the homozygous (−/−) mice was significantly higher compared to their wild-type (+/+) littermates. However, the wild-type (+/+) mice displayed higher sensitivity to the anxiolytic-like action of diazepam. Even the lowest dose of diazepam (0.5 mg/kg) induced a significant increase of open arm entries in the wild-type (+/+) mice. A similar effect in the homozygous (−/−) mice was established after the administration of diazepam 1 mg/kg. The highest dose of diazepam (3 mg/kg) caused a prominent anxiolytic-like effect in the wild-type (+/+) mice, whereas in the homozygous (−/−) animals suppression of locomotor activity was evident. The performance of the homozygous (−/−) mice in the rotarod test did not differ from that of the wild-type (+/+) littermates. However, a difference between the wild-type (+/+) and homozygous (−/−) animals became evident after treatment with diazepam. Diazepam (0.5 and 3 mg/kg) induced significantly stronger impairment of motor co-ordination in the homozygous (−/−) mice compared to their wild-type (+/+) littermates. The density of benzodiazepine binding sites was increased in the cerebellum, but not in the cerebral cortex and hippocampus, of the homozygous (−/−) mice.
Female mice lacking CCK2 receptors are less anxious than their wild-type (+/+) littermates. The reduced anxiety in homozygous (−/−) mice probably explains why the administration of a higher dose of diazepam is necessary to induce an anxiolytic-like action in these animals. The highest dose of diazepam (3 mg/kg) induced significantly stronger suppression of locomotor activity and impairment of motor co-ordination in the homozygous (−/−) mice compared to the wild-type (+/+) littermates. The increase in the action of diazepam is probably related to the elevated density of benzodiazepine receptors in the cerebellum of homozygous (−/−) mice. The present study seems to be in favour of increased tone of the GABAergic system in mice without CCK2 receptors.
KeywordsTargeted mutagenesis Wild-type Heterozygous Homozygous Benzodiazepine receptors GABA Diazepam Cholecystokinin Cholecystokinin2 receptors Rotarod test Motor co-ordination Elevated plus-maze Exploratory behaviour Anxiety
This study was supported by the James S. McDonnell Foundation (USA) and by grant no. 3922 of the Estonian Science Foundation.
- Bradwejn J, Vasar E (1995) Cholecystokinin and panic disorder. In: Bradwejn J, Vasar E (eds) Cholecystokinin and anxiety: from neuron to behavior. R.B. Landes, Austin, pp 73–86Google Scholar
- Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, San DiegoGoogle Scholar
- Harro J (1993) Studies on the brain cholecystokinin receptors and behaviour (dissertation). Acta Universitatis Upsaliensis, v. 421. Uppsala University Press, Uppsala, pp 42Google Scholar
- Kõks S, Vasar E, Soosaar A, Lang A, Volke, Võikar V, Bourin M, Männistö PT (1997) Relation of exploratory of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. Eur Neuropsychopharmacol 7:289–294Google Scholar
- Kõks S. Männistö PT, Bourin M, Shlik J, Vasar V, Vasar E (2000) Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. J Psychiatr Neurosci 25:33–42Google Scholar
- Kõks S, Volke V, Veraksitš A, Rünkorg K, Sillat T, Abramov U, Bourin M, Huotari M, Männistö PT, Matsui T, Vasar E (2001) Cholecystokinin2 receptor deficient mice display altered function of brain dopaminergic system. Psychopharmacology 158:198–204Google Scholar
- Kõks S, Abramov U, Veraksitš A, Bourin M, Matsui T, Vasar E (2003) CCK2 receptor-deficient mice have increased sensitivity of dopamine D2 receptors. Neuropeptides 37:25–29Google Scholar
- Mason C, Sotelo C (eds) (1997) The cerebellum: a model for construction of a cortex. Perspect Dev Neurobiol 5:1–95Google Scholar
- Miller KK, Hoffer A, Svoboda KR, Lupica CR (1997) Cholecystokinin increases GABA release by inhibiting a resting K+ conductance in hippocampal interneurons. J Neurosci 13:4994–5003Google Scholar
- Powell KR, Barrett JE (1991) Evaluation of the effects of PD 134308 (CI-988), a CCKB antagonist, on the punished responding of squirrel monkeys. Neuropeptides 19:75–78Google Scholar
- Rägo L, Kiivet RA, Harro J, Põld (1988) Behavioral differences in an elevated plus-maze: correlation between anxiety and decreased number of GABA and benzodiazepine receptors in mouse cerebral cortex. Naunyn-Schmiedeberg's Arch Pharmacol 337:675–678Google Scholar
- Rodgers RJ, Cao B-J, Dalvi A, Holmes A (1997) Animal models of anxiety: an ethological perspective. Brazil J Med Biol Res 30:289–304Google Scholar
- Sebret A, Léna I, Crété D, Matsui T, Roques BP, Daugé V (1999) Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. J Neurosci 19:7230–7237Google Scholar
- Shlik J, Vasar E, Bradwejn J (1997) Cholecystokinin and psychiatric disorders: role in aetiology and potential of receptor antagonists in therapy. CNS Drugs 8:134–152Google Scholar
- Vasar E, Kõks S, Beljajev S, Abramov U, Koovit I, Matsui T (2000) CCKB receptor knockout mice: gender related behavioural differences. Eur Neuropsychopharmacol 10:S69Google Scholar
- Vasar E, Raud S, Veraksitš A, Rünkorg K, Matsui T, Bourin M, Greengrass CJ, Volke V, Kõks S (2002) Mice lacking CCK2 receptors display reduced anxiety in the plus-maze. Eur Psychiatr Suppl 1:50Google Scholar